Brief: Enveric Biosciences Reports Positive Preclinical Results From Phototoxicity Analysis For Lead Neuroplastogen Candidate Eb-003
19/05/2026 13:41
May 19 (Reuters) - Enveric Biosciences Inc ENVB.O: ENVERIC BIOSCIENCES REPORTS POSITIVE PRECLINICAL RESULTS FROM PHOTOTOXICITY ANALYSIS FOR LEAD NEUROPLASTOGEN CANDIDATE EB-003 ENVERIC BIOSCIENCES INC - EB-003 SHOWS NO PHOTOREACTIVE POTENTIAL IN PRECLINICAL ANALYSIS ENVERIC BIOSCIENCES INC - EB-003 FIRST KNOWN COMPOUND TO SELECTIVELY ENGAGE 5-HT2A AND 5-HT1B RECEPTORS Source text: ID:nBwb1jCVja Further company coverage: ENVB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enveric Biosciences
See all newsBrief: Enveric Biosciences Announces Positive Results From IND-Enabling ADMET Studies
Enveric Biosciences Q2 net loss widens
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer
Brief: Enveric Biosciences Initiates Investigational New Drug (IND)-Enabling Genotoxicity Studies Of Lead Neuroplastogen Candidate EB-003
Brief: Enveric Biosciences Reports Positive Preclinical Results From Phototoxicity Analysis For Lead Neuroplastogen Candidate Eb-003